Press coverage about Summit Therapeutics (NASDAQ:SMMT) has been trending somewhat positive on Tuesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.404885371462 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Summit Therapeutics (NASDAQ:SMMT) traded up $0.05 on Tuesday, reaching $12.25. 54,500 shares of the company’s stock were exchanged, compared to its average volume of 109,363. The stock has a market cap of $168.90, a price-to-earnings ratio of -122.50 and a beta of 0.73. Summit Therapeutics has a 1-year low of $8.80 and a 1-year high of $16.86.
Summit Therapeutics (NASDAQ:SMMT) last posted its quarterly earnings data on Wednesday, December 6th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.53. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.32 million. Summit Therapeutics had a negative return on equity of 10.90% and a negative net margin of 0.95%. equities research analysts anticipate that Summit Therapeutics will post -0.46 earnings per share for the current year.
WARNING: “Summit Therapeutics (SMMT) Receiving Somewhat Favorable Press Coverage, Study Finds” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3226101/summit-therapeutics-smmt-receiving-somewhat-favorable-press-coverage-study-finds.html.
Summit Therapeutics Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.